. 2023 Feb 1;38(2):71–81. doi: 10.1007/s40211-022-00455-8

Table 2.

Neuropsychological performance of diagnostic subgroups

	HC	SCD	MCI	AD	∑
MMSE (0–30)*** Mdn (IQR)	28.73 ± 1.04 29 (28–30)	28.75 ± 1.18 29 (28–30)	27.46 ± 1.99 28 (26–29)	20.41 ± 4.05 21 (19–23)	25.2 ± 4.53 27 (23–29)
CDT (0–10)*** Mdn (IQR)	9.12 ± 1.85 10 (9–10)	8.97 ± 1.70 10 (9–10)	8.39 ± 2.08 9 (8–10)	5.73 ± 2.56 5 (4–8)	7.55 ± 2.6 9 (5–10)
VVT 3.0 Screening (0–10)*** Mdn (IQR)	9.61 ± 0.66 10 (9–10)	9.51 ± 0.94 10 (9–10)	9.14 ± 1.24 10 (9–10)	6.90 ± 2.76 8 (5–9)	8.41 ± 2.2 9 (8–10)

SCD

MCI

∑

Test procedure

n = 33

n = 68

n = 301

n = 220

n = 622

MMSE (0–30)***

Mdn (IQR)

28.73 ± 1.04

29 (28–30)

28.75 ± 1.18

29 (28–30)

27.46 ± 1.99

28 (26–29)

20.41 ± 4.05

21 (19–23)

25.2 ± 4.53

27 (23–29)

CDT (0–10)***

Mdn (IQR)

9.12 ± 1.85

10 (9–10)

8.97 ± 1.70

10 (9–10)

8.39 ± 2.08

9 (8–10)

5.73 ± 2.56

5 (4–8)

7.55 ± 2.6

9 (5–10)

VVT 3.0 Screening (0–10)***

Mdn (IQR)

9.61 ± 0.66

10 (9–10)

9.51 ± 0.94

10 (9–10)

9.14 ± 1.24

10 (9–10)

6.90 ± 2.76

8 (5–9)

8.41 ± 2.2

9 (8–10)

HC Healthy controls, SCD Subjective cognitive decline, MCI Mild cognitive impairment, AD Alzheimer’s dementia, MMSE Mini Mental Status Examination, CDT Clock drawing test, VVT 3.0 Screening Vienna Visuo-constructive Test 3.0 Screening, Mdn median, IQR interquartile range, scores are reported as mean ± standard deviation and Mdn (IQR), Kruskal–Wallis test was performed to assess differences in data

***p < 0.001